The cutting-edge advances in multivalent mRNA–exosome vaccines provides a mechanistic blueprint showing how these customized mRNA payloads can systematically reprogram the immunosuppressive architecture of “cold” tumor microenvironments and mobilize potent, antigen-specific cytotoxic T-lymphocyte responses to overcome cancer immunotherapy resistance.A primary challenge in oncology vaccinology is delivering payloads to lymphoid-resident antigen-presenting cells (APCs) without triggering systemic toxicities or rapid hepatic clearance. While synthetic lipid nanoparticles (LNPs) are standard for systemic delivery, they face hepatocyte sequestration driven by blood-borne apolipoprotein E (ApoE) binding, which limits extrahepatic bioavailability. To bypass this constraint, engineered exosomes offer a biological alternative. These cell-derived vesicles feature a native lipid bilayer enriched with cholesterol and sphingomyelin that shields mRNA from ribonuclease degradation. By presenting surface markers like CD47—a “don’t eat me” signal blocking macrophage phagocytosis via SIRPα—exosomes achieve extended circulation half-lives (Figure 1).

Indolent B-cell non-Hodgkin lymphomas (iNHLs) represent a biologically heterogeneous group of hematological malignancies characterized by slow progression and extended survival, yet most cases remain incurable with frequent relapses. This prospective, multicenter, single-arm clinical trial evaluated the efficacy and safety of obinutuzumab plus bendamustine (GB) as first-line treatment for 220 Chinese patients with newly diagnosed indolent B-cell lymphoma across eight centers. The study encompassed multiple iNHL subtypes including follicular lymphoma (FL), marginal zone lymphoma, Waldenström macroglobulinemia, hairy cell leukemia variant, and unclassified B-cell lymphoproliferative disorder. Patients received six induction cycles of GB followed by two years of obinutuzumab maintenance in responders. At a median follow-up of 13.1 months, the regimen demonstrated remarkably high overall response rates across all subtypes, with particularly impressive complete response rates. The FL and non-FL groups showed comparable overall response rates, although the FL group achieved a significantly higher complete response rate. Treatment-emergent adverse events were generally manageable, though infections were more frequent in the non-FL group. Multivariate analysis identified elevated beta-2 microglobulin levels and failure to complete all planned treatment cycles as independent predictors of shorter progression-free survival.

Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies worldwide, ranking as the third leading cause of cancer-related mortality, with limited therapeutic targets and dismal prognosis for advanced disease. This study identifies P53 and DNA damage-regulated gene 1 (PDRG1) as a novel oncogenic driver in HCC, revealing a previously unrecognized regulatory axis promoting tumor progression. The researchers demonstrate that PDRG1 expression is significantly upregulated in HCC tissues compared with normal liver, and that high PDRG1 expression correlates with advanced tumor stage, higher histological grade, and poor patient survival, establishing PDRG1 as a potential prognostic biomarker. Functional studies reveal that PDRG1 knockdown suppresses HCC cell proliferation, migration, and invasion in vitro, and inhibits tumor growth and lung metastasis in vivo, while PDRG1 overexpression exerts opposite effects. Mechanistically, PDRG1 activates Wnt/β-catenin signaling, elevating levels of β-catenin, c-Myc, and phosphorylated GSK-3β, and the oncogenic effects of PDRG1 are reversed by the Wnt pathway inhibitor XAV939, confirming functional dependence on this pathway. Furthermore, the study identifies transcription factor Specificity Protein 1 (SP1) as an upstream regulator that binds directly to the PDRG1 promoter and activates its transcription, with rescue experiments confirming that SP1 exerts its pro-tumor effects through PDRG1.

Pleural infection, encompassing empyema and complicated parapneumonic effusion, represents a serious infectious condition associated with significant morbidity and mortality, yet comprehensive data distinguishing between hospital-acquired (HAPI) and community-acquired (CAPI) forms remain limited. This large retrospective study conducted over 11 years at a major Chinese tertiary-care hospital analyzed 832 patients with pleural infection, providing one of the largest cohorts reported to date. The study revealed that HAPI accounted for the vast majority of cases (84.9%), with important differences in etiology, predisposing factors, microbiology, and antimicrobial resistance patterns compared with CAPI. The most common cause of CAPI was pneumonia and pleurisy, whereas trauma or chest surgery predominated in HAPI. Significant differences in predisposing factors were identified, including abdominal indwelling catheter use, prolonged thoracic cavity drainage, and broad-spectrum antibiotic use, all more prevalent in HAPI. Microbiological analysis revealed distinct pathogen profiles, with Staphylococcus epidermidis and Streptococcus species predominating in HAPI and CAPI respectively, while Acinetobacter baumannii and Escherichia coli were the most common Gram-negative pathogens. Alarmingly, high rates of antimicrobial resistance were observed, particularly among Gram-negative organisms. The overall 30-day mortality was 13.1%, with no significant difference between HAPI and CAPI.

Seven-transmembrane (7TM) proteins are large, complex molecules with important biological functions, but high-resolution NMR structural data for 7TM proteins has eluded researchers. Recently, a team from Japan achieved high-resolution solid-state NMR (SSNMR) data for fully protonated SzR1, a 7TM protein, in a fully hydrated lipid bilayer utilizing ultrafast magic angle spinning (MAS) NMR at 160 kHz using a 0.4mm rotor.

A new review in Medicine Plus outlines a transformative paradigm for luminal cancers using engineered microbe-based micro/nanorobots. Deployed via oral, suppository, or intracavitary routes, these living platforms bypass physiological barriers, colonize tumor niches, continuously synthesize therapeutics, and remodel the tumor microenvironment. Merging microbial adaptability with synthetic biology, they usher in an era of persistent, spatially controlled intervention.

A new review in Medicine Plus traces the evolution of mRNA lipid nanoparticles (mRNA-LNPs) from prophylactic vaccine vehicles to programmable therapeutic platforms. The authors detail clinical and preclinical progress across infectious disease, cancer, autoimmunity, rare genetic disease and tissue repair, while identifying key translational hurdles including extrahepatic targeting, repeat-dose immunogenicity, off-target editing risks, and scalable manufacturing.